Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTNM NASDAQ:MREO NASDAQ:NGNE NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$11.88-2.3%$10.22$3.35▼$20.24$333.14M1.29152,549 shs73,368 shsMREOMereo BioPharma Group$1.96-6.7%$1.78$1.47▼$4.72$311.64M0.451.64 million shs1.08 million shsNGNENeurogene$30.21-4.3%$19.92$6.88▼$74.49$431.10M1.58220,996 shs251,385 shsUNCYUnicycive Therapeutics$4.44-6.1%$4.24$3.53▼$11.00$78.41M1.86383,548 shs322,877 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics0.00%+13.12%-2.88%+210.20%-25.03%MREOMereo BioPharma Group+7.14%+2.44%+15.38%+30.43%-49.28%NGNENeurogene+22.18%+50.43%+63.95%+47.27%-36.31%UNCYUnicycive Therapeutics-0.84%+2.38%+7.99%-5.59%+30.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$11.88-2.3%$10.22$3.35▼$20.24$333.14M1.29152,549 shs73,368 shsMREOMereo BioPharma Group$1.96-6.7%$1.78$1.47▼$4.72$311.64M0.451.64 million shs1.08 million shsNGNENeurogene$30.21-4.3%$19.92$6.88▼$74.49$431.10M1.58220,996 shs251,385 shsUNCYUnicycive Therapeutics$4.44-6.1%$4.24$3.53▼$11.00$78.41M1.86383,548 shs322,877 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics0.00%+13.12%-2.88%+210.20%-25.03%MREOMereo BioPharma Group+7.14%+2.44%+15.38%+30.43%-49.28%NGNENeurogene+22.18%+50.43%+63.95%+47.27%-36.31%UNCYUnicycive Therapeutics-0.84%+2.38%+7.99%-5.59%+30.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTNMContineum Therapeutics 3.00Buy$22.2086.87% UpsideMREOMereo BioPharma Group 2.83Moderate Buy$7.40277.55% UpsideNGNENeurogene 2.56Moderate Buy$46.1752.82% UpsideUNCYUnicycive Therapeutics 2.75Moderate Buy$57.001,183.78% UpsideCurrent Analyst Ratings BreakdownLatest UNCY, MREO, NGNE, and CTNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.0010/8/2025CTNMContineum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MREOMereo BioPharma GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NGNENeurogeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025UNCYUnicycive TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/2/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$45.009/27/2025CTNMContineum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MREOMereo BioPharma GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NGNENeurogeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025UNCYUnicycive TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025CTNMContineum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTNMContineum TherapeuticsN/AN/AN/AN/A$7.66 per shareN/AMREOMereo BioPharma Group$500K623.28N/AN/A$0.39 per share5.03NGNENeurogene$930K463.54N/AN/A$20.89 per share1.45UNCYUnicycive Therapeutics$680K115.31N/AN/A$0.72 per share6.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTNMContineum Therapeutics-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%11/5/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-80.00%-66.94%11/11/2025 (Estimated)NGNENeurogene-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)UNCYUnicycive Therapeutics-$36.73M-$4.12N/AN/AN/AN/A-243.13%-119.46%11/12/2025 (Estimated)Latest UNCY, MREO, NGNE, and CTNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025CTNMContineum Therapeutics-$0.54N/AN/AN/A$6.00 millionN/A8/14/2025Q2 2025UNCYUnicycive Therapeutics-$0.70-$0.52+$0.18-$0.52N/AN/A8/12/2025Q2 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$7.80 million$0.50 million8/11/2025Q2 2025NGNENeurogene-$1.15-$1.05+$0.10-$1.05N/AN/A8/5/2025Q2 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTNMContineum TherapeuticsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTNMContineum TherapeuticsN/A24.5124.51MREOMereo BioPharma GroupN/A8.138.13NGNENeurogeneN/A18.0718.07UNCYUnicycive TherapeuticsN/A2.182.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTNMContineum TherapeuticsN/AMREOMereo BioPharma Group62.83%NGNENeurogene52.37%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipCTNMContineum Therapeutics11.30%MREOMereo BioPharma Group5.50%NGNENeurogene11.64%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTNMContineum Therapeutics3128.04 million24.87 millionN/AMREOMereo BioPharma Group40159.00 million150.26 millionOptionableNGNENeurogene9014.27 million12.61 millionOptionableUNCYUnicycive Therapeutics917.66 million15.77 millionNot OptionableUNCY, MREO, NGNE, and CTNM HeadlinesRecent News About These CompaniesSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive1 hour ago | prnewswire.comHolzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics (UNCY) and KinderCare Learning Companies, Inc. (KLC)4 hours ago | globenewswire.comUNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges Investor to Contact the Firm Before the October 14th DeadlineOctober 10 at 1:57 PM | globenewswire.comUNCY LAWSUIT ALERT: Levi & Korsinsky Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOctober 10 at 9:00 AM | prnewswire.comROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure ...October 10 at 2:55 AM | caledonianrecord.comCInvestors in Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights - Contact Levi & Korsinsky Before October 14, 2025October 10 at 2:55 AM | theglobeandmail.comROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCYOctober 9 at 11:26 PM | globenewswire.comUnicycive Therapeutics' (UNCY) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 9 at 9:38 PM | marketbeat.comInvestors in Unicycive Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights – UNCYOctober 9 at 4:23 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. InvestorsOctober 9 at 3:32 PM | globenewswire.comUNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 9 at 12:00 PM | globenewswire.comClass Action Filed Against Unicycive Therapeutics, Inc. (UNCY) Seeking Recovery for Investors - Contact The Gross Law FirmOctober 9 at 8:45 AM | prnewswire.comUNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitOctober 8 at 10:45 PM | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCYOctober 8 at 4:30 PM | prnewswire.comUNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsOctober 8 at 10:45 AM | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 14, 2025 in ...October 6, 2025 | caledonianrecord.comCROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCYOctober 6, 2025 | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 14, 2025 in Unicycive Therapeutics, Inc. Lawsuit – UNCYOctober 6, 2025 | globenewswire.comUNICYCIVE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the October 14th Deadline in the Unicycive Class Action LawsuitOctober 6, 2025 | globenewswire.comShareholders that lost money on Unicycive Therapeutics, Inc.(UNCY) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreOctober 6, 2025 | prnewswire.comUNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UnicyciveOctober 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUNCY, MREO, NGNE, and CTNM Company DescriptionsContineum Therapeutics NASDAQ:CTNM$11.88 -0.28 (-2.30%) Closing price 04:00 PM EasternExtended Trading$11.87 -0.01 (-0.08%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Mereo BioPharma Group NASDAQ:MREO$1.96 -0.14 (-6.67%) Closing price 04:00 PM EasternExtended Trading$1.98 +0.02 (+0.82%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Neurogene NASDAQ:NGNE$30.21 -1.35 (-4.28%) Closing price 04:00 PM EasternExtended Trading$30.00 -0.21 (-0.70%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Unicycive Therapeutics NASDAQ:UNCY$4.44 -0.29 (-6.13%) Closing price 04:00 PM EasternExtended Trading$4.54 +0.10 (+2.34%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
